Bovine colostrum—the “first milk” produced in the first days after calving—is naturally enriched with immune-active proteins, growth factors, and protective peptides. Among these, lactoferrin stands out as a multifunctional iron-binding glycoprotein with antibacterial, antiviral, anti-inflammatory, and immunomodulatory effects. MDPI+1  When colostrum supplements retain biologically active lactoferrin, they offer a focused way to support the immune system, enhance resistance to upper respiratory infections, and even influence sleep quality through the gut–brain–immune axis. It is important to recognize that not all colostrum products are equivalent. Some are overly processed, diluted, or derived from later milkings, which markedly reduces their lactoferrin content. Clinically, the benefits described below are most relevant to preparations with quantified, biologically active lactoferrin, rather than generic “colostrum” powders without standardization. How Lactoferrin-Containing Colostrum Works Lactoferrin exerts its effects through several complementary mechanisms. As an iron-binding protein, it limits free iron availability to bacteria, inhibiting their growth and biofilm formation. It also interacts directly with viral particles and host cell receptors, blocking viral attachment and entry for a range of respiratory viruses. PMC+1  At the mucosal surface, lactoferrin enhances secretory IgA, supports tight junction integrity, and modulates innate cells such as neutrophils, dendritic cells, and natural killer (NK) cells. Nature+1 Colostrum itself supplies a matrix of immunoglobulins, proline-rich polypeptides, growth factors, and oligosaccharides that act as prebiotics and trophic factors for the gut epithelium. Contemporary reviews highlight bovine colostrum as a promising adjunct for respiratory and gastrointestinal infections and as a supportive strategy during viral epidemics, including COVID-19. Frontiers+1  When combined, colostrum and its lactoferrin fraction support both barrier defense and systemic immune regulation. Clinical Evidence for Immune and Upper Respiratory Protection Multiple randomized and controlled clinical trials support the role of lactoferrin and colostrum in reducing the frequency and severity of upper respiratory tract infections (URTIs). A meta-analysis of randomized trials involving nearly 1,200 participants found that lactoferrin supplementation reduced the odds of respiratory tract infections by about 40–45% compared with contro l. PubMed  In healthy adults, a 12-week randomized, double-blind trial of bovine lactoferrin (200 mg/day) demonstrated fewer respiratory and systemic symptoms, alongside enhanced plasmacytoid dendritic cell (pDC) function—key sentinels for antiviral defense. MDPI Colostrum itself has been studied in several populations. In children with recurrent URTIs and diarrhea, a 4-week course of bovine colostrum significantly reduced total infections, URTI episodes, and hospitalizations over the following six months. PubMed  A randomized trial in medical university students showed that moderate-dose colostrum supplementation lowered the incidence of URTIs compared with placebo, with benefits persisting for weeks after cessation. MDPI  Earlier athletic studies have also reported fewer URTI symptoms and shortened illness duration in heavily trained adults receiving colostrum, consistent with colostrum’s capacity to counteract exercise-induced immune suppression . PMC+1 Mechanistically, lactoferrin and colostrum appear to reduce respiratory susceptibility by: Enhancing type I interferon responses and NK cell activity Supporting mucosal IgA production and epithelial integrity Limiting pathogen adhesion and biofilm formation along the nasopharyngeal and intestinal mucosae These effects align with the clinical observation that URTIs become less frequent and less severe in individuals taking standardized lactoferrin-containing colostrum over several weeks. Lactoferrin, Sleep Quality, and the Gut–Brain–Immune Axis Although most people think of lactoferrin as purely an “immune protein,” emerging research suggests it can influence sleep and circadian regulation via neuroinflammatory and gut-brain pathways. A randomized, double-blind, placebo-controlled trial in young children using a lactoferrin-fortified formula (48 mg/day) over 13 weeks showed improved morning behavior and reduced “hard to wake up” scores compared with placebo, suggesting better sleep quality even though total sleep time did not change. PubMed In adults, pilot work with liposomal lactoferrin has demonstrated improved subjective and actigraphy-measured sleep quality and reduced jetlag after long-haul travel, potentially through suppression of hippocampal neuroinflammation and modulation of inflammatory cytokines that perturb sleep architecture. MDPI  Earlier randomized studies in “poor sleepers” likewise indicate better perceived depth of sleep and morning refreshment with lactoferrin, in parallel with improvements in the enteric environment—highlighting the relevance of the gut–brain axis. MDPI+1 When colostrum serves as the delivery vehicle for lactoferrin, patients may gain both nocturnal immune support (particularly relevant during viral seasons) and subtle normalization of sleep quality. Clinically, this pairing is attractive for individuals whose sleep is degraded by recurrent infections, travel, chronic inflammation, or low-grade dysbiosis. Practical Considerations and Product Quality From a safety perspective, bovine lactoferrin has been granted “generally recognized as safe” (GRAS) status by regulatory authorities and approved as a novel food ingredient in the European Union. MDPI+1  Trials across infants, children, adults, and older adults consistently report good tolerability, with adverse events comparable to placebo. However, not all colostrum products meaningfully deliver lactoferrin. Factors that can reduce bioactive lactoferrin include late collection (beyond the true colostrum window), aggressive heat treatment, defatting and fractionation processes, or dilution with standard whey or milk powders. As a result, a label that simply reads “bovine colostrum” does not guarantee significant lactoferrin content. Patients seeking the immune and sleep-related benefits described above should look for products that: Declare standardized lactoferrin content (e.g., mg of lactoferrin per serving) Use low-temperature processing and early-milking colostrum Provide third-party testing for active proteins where available Dosages used in clinical trials vary, but commonly range from 40–200 mg/day of purified lactoferrin for children and adults, with colostrum doses typically in the grams-per-day range. PubMed+2MDPI+2  Individual needs, comorbidities, and concomitant therapies should be considered in consultation with a qualified clinician. Pharmaceutical Grade Lactoferrin Containing Colostrum Conclusion Lactoferrin-rich colostrum occupies a unique niche at the intersection of mucosal immunity, systemic inflammatory control, and sleep regulation. By combining the broad matrix of colostrum with the targeted antiviral, antibacterial, and immunomodulatory activity of lactoferrin, these preparations can reduce the burden of upper respiratory infections, support resilient immune function, and modestly improve sleep quality in selected populations. As with any therapeutic nutrient, careful attention to product selection, dose, and clinical context is essential—but the evidence base for lactoferrin-containing colostrum as a safe, physiology-aligned adjunct continues to grow. References Miyakawa M, Kubo S, Oda H, et al. Effects of lactoferrin on sleep conditions in children aged 12–32 months: a preliminary, randomized, double-blind, placebo-controlled trial. Nat Sci Sleep. 2020;12:671-677. doi:10.2147/NSS.S263106. PubMed Uesaki S, et al. Liposomal lactoferrin reduces brain neuroinflammation in rats and alleviates jetlag and improves sleep quality after long-haul travel. NeuroSci. 2025;6(1):19. doi:10.3390/neurosci6010019. MDPI Oda H, et al. Effects of bovine lactoferrin on the maintenance of respiratory and systemic physical conditions in healthy adults: a randomized, double-blind, placebo-controlled trial. Nutrients. 2023;15(18):3959. doi:10.3390/nu15183959. MDPI Ali AS, Hasan SS, Kow CS, Merchant HA. Lactoferrin reduces the risk of respiratory tract infections: a meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2021;45:26-32. doi:10.1016/j.clnesp.2021.08.019. PubMed+1 Manzoni P, et al. Lactoferrin supplementation in preventing and protecting from SARS-CoV-2 infection: an updated review of literature. Int J Mol Sci. 2024;25(19):10248. doi:10.3390/ijms251910248. MDPI Hong R, Xie X, Zhou Q, et al. A comprehensive review of research advances in the study of lactoferrin bioactivity and mechanisms. Food Funct. 2024;15(3):xxxx-xxxx. doi:10.1039/d4fo02083a. RSC Publishing Eker F, et al. The potential of lactoferrin as antiviral and immune-modulating agent: current evidence and future perspectives. J Med Virol. 2024;xx(x):xxxx-xxxx. PMC Kim JW, et al. The multifaceted functions of lactoferrin in antimicrobial defense and immune modulation. Biomolecules. 2025;15(8):1174. doi:10.3390/biom15081174. MDPI Siqueiros-Cendón T, Arévalo-Gallegos S, Iglesias-Figueroa BF, et al. Immunomodulatory effects of lactoferrin. Acta Pharmacol Sin. 2014;35(5):557-566. doi:10.1038/aps.2013.200. Nature Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. J Cell Mol Med. 2009;13(9B):2971-2984. PMC Kell DB, Heyden EL, Pretorius E. The biology of lactoferrin, an iron-binding protein that can help defend against viral infection and inflammation. Front Immunol. 2020;11:1221. doi:10.3389/fimmu.2020.01221. Frontiers Saad K, Abo-Elella SSA, El-Baseer KAA, et al. Effects of bovine colostrum on recurrent respiratory tract infections and diarrhea in children. Medicine (Baltimore). 2016;95(37):e4560. doi:10.1097/MD.0000000000004560. PubMed Baśkiewicz-Hałasa M, Stachowska E, Grochans E, et al. Moderate dose bovine colostrum supplementation in prevention of upper respiratory tract infections in medical university students: a randomized, triple blind, placebo-controlled trial. Nutrients. 2023;15(8):1925. doi:10.3390/nu15081925. MDPI Brinkworth GD, Buckley JD. Concentrated bovine colostrum protein supplementation reduces the incidence of self-reported symptoms of upper respiratory tract infection in adult males. Eur J Nutr. 2003;42(4):228-232. Worldwide Journals Jones AW, Cameron SJ, Thatcher R, et al. Effects of bovine colostrum supplementation on upper respiratory illness in active males. Brain Behav Immun. 2014;39:194-203. Worldwide Journals Galdino ABS, Rangel AHDN, Buttar HS, et al. Bovine colostrum: benefits for the human respiratory system and potential contributions for clinical management of COVID-19. Food Agric Immunol. 2021;32(1):143-162. doi:10.1080/09540105.2021.1892594. ResearchGate Duman H, et al. Bovine colostrum and its potential contributions for prevention and treatment of COVID-19 and other respiratory infections. Front Immunol. 2023;14:1214514. Frontiers Burton C, et al. Impact of lactoferrin supplementation on respiratory tract infections in an elderly population: randomized, double-blind, placebo-controlled study. Clin Nutr ESPEN. 2023;xx(x):xxxx-xxxx. ScienceDirect Oda H, et al. Maintenance of respiratory and systemic conditions by bovine lactoferrin and plasmacytoid dendritic cell activation: randomized controlled data. Nutrients. 2020;12(9):xxxx-xxxx. MDPI Miyakawa M, Abe F, Nomiyama T. Clinical research review: usefulness of bovine lactoferrin in pediatric and adult health, with a focus on sleep and neurodevelopment. Biometals. 2023;36(3):543-560. SpringerLink Subscribe to our Blog   Sponsored by Stages of Life Vitamins 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

Back pain that refuses to respond to “standard” spine care is often labeled nonspecific or degenerative. One under-recognized culprit is injury or entrapment of the cluneal nerves – the superior, middle, and inferior sensory branches that carry pain from the lower back and buttock skin. When these nerves are irritated or compressed, patients can develop surprisingly severe pain that mimics lumbar disc disease, sacroiliac (SI) joint dysfunction, or even sciatica, yet the spine itself may be structurally normal. NCBI+1 Causes of Damage to the Cluneal Nerves This problem does not occur by chance. It usually follows some type of trauma, most commonly diagnosed well after the trauma has become a memory. That is, the latency of onset is frequently measured in years rather than minutes or weeks. This nerve group can be damaged through direct trauma, although the precise nerve that is damaged can be predicted based upon the nature of the trauma. That is, some things are more likely to cause certain pain syndromes, in predictable ways. The most commonly damaged of the Cluneal Nerves is the Superior Cluneal Nerve group. The nerves travel over the hip bone, the Iliac Crest, and it is at this point that they are most vulnerable. Typical Causes : 1. Surgical Trauma from a stainless steel retractor used during laminectomy. 2. Swelling following lumbar surgery 3. Bone harvest (Iliac Crest) necessary to do non-cadaveric 'fusion surgery.' 4. Blunt compression from hard surfaces, such as radiology tables, hard surfaces 5. Lastly, compression trauma from direct injury, such as being kicked, punched 6. Motor vehicle injury. Injury to the Inferior Cluneal Nerve is the next most common of the group to be injured. Typical Causes : 1. Pressure following prolonged surgery in the supine position 2. Repeated pressure from sitting, direct weight bearing on the nerve as it passes over bone. 3. Radiation Therapy to the perineum, including prostate and rectal cancer Injury to the Middle Cluneal Nerve: Typical Causes : 1. Blunt trauma to the posterior pelvis 2. Surgery to the Sacrum or Cauda Equina 3. Prolonged postural changes from lower extremity gait abnormality 4. Radiation Therapy to the Pelvis Anatomy: the three cluneal nerve groups The superior cluneal nerves (SCN)  arise from the dorsal rami of approximately L1–L3 and descend through the thoracolumbar fascia to cross the posterior iliac crest in tight osteofibrous tunnels before supplying the upper buttock skin. Entrapment most commonly occurs where these branches cross the iliac crest, making them particularly vulnerable to mechanical irritation, fascial thickening, or scar formation. NCBI+1 The middle cluneal nerves (MCN)  originate from the dorsal rami of S1–S3 and course through or under the long posterior sacroiliac ligament to supply the medial buttock. Their entrapment often produces deep aching or burning pain over the sacrum with radiation toward the posterior thigh – sometimes diagnosed as “pseudo-sciatica.” PubMed+1 The inferior cluneal nerves (ICN)  are distal branches of the posterior femoral cutaneous nerve. They innervate the lower buttock, just below the gluteal fold, and may be injured with trauma, pelvic or hip surgery, prolonged sitting on hard surfaces, or local compression. Neuropathy of these branches (sometimes termed clunealgia ) causes focal pain in the lower gluteal region and may radiate along the proximal posterior thigh. ScienceDirect+1 Clinical presentation and pain distribution Cluneal neuropathy typically presents as unilateral, localized buttock and low back pain  that is worse with specific postures or mechanical loading and better with rest or local anesthetic block. Superior cluneal nerve pain Burning, stabbing, or aching pain over the posterior iliac crest and upper buttock , often 7–8 cm lateral to the midline. Exacerbated by lumbar extension, prolonged standing, walking, or lumbar rotation. Frequently misdiagnosed as facet arthropathy, L5 radiculopathy, or SI joint pain. Surgical Neurology International+1 Middle cluneal nerve pain Deep aching pain over the sacrum and medial buttock , sometimes radiating to the posterior thigh. May mimic sacroiliitis or piriformis syndrome; often described as “sciatica” despite normal imaging. Sciatica ALWAYS presents with pain all the way to the toes. Provoked by pressure over the long posterior sacroiliac ligament about 3–4 cm below the SCN trigger zone. SpringerLink+1 Inferior cluneal nerve pain Focal pain in the lower buttock/inferior gluteal crease , aggravated by sitting, cycling, or direct compression. Can be confused with hamstring tendinopathy, ischial bursitis, or pelvic floor pain. ScienceDirect+1 Neurologic exam is generally normal aside from tender trigger points  and allodynia or hyperalgesia  over the cutaneous territory, emphasizing the purely sensory nature of these nerves. NCBI+1 Diagnosis 1. History and physical examination Diagnosis is primarily clinical: Focal tenderness  along the iliac crest (SCN), over the long posterior SI ligament (MCN), or at/below the gluteal fold (ICN). Reproduction of the patient’s typical pain with sustained pressure or specific provocative maneuvers (e.g., lumbar extension or lateral bending to the contralateral side). Pain Physician Pain that does not follow a classic dermatomal pattern  and lacks associated motor deficit or reflex changes. Importantly, cluneal neuropathy should be considered in patients with: Chronic low back or buttock pain with normal or inconclusive lumbar imaging . Persistent pain after lumbar surgery or sacroiliac fusion despite anatomically satisfactory procedures. Neurospine+1 2. Diagnostic nerve blocks The gold-standard confirmatory test  is a diagnostic cluneal nerve block : Small volume local anesthetic (with or without steroid) is injected at the suspected entrapment site under ultrasound or fluoroscopic guidance. Temporary, substantial pain relief (commonly defined as ≥50–80% reduction) strongly supports the diagnosis and identifies the symptomatic nerve group. SpringerOpen+2Neurospine+2 3. Imaging and electrodiagnostics Conventional MRI, CT, and EMG are often normal but play a role in excluding competing diagnoses  (disc herniation, spinal stenosis, sacroiliitis, hip pathology). High-resolution ultrasound and MR neurography can sometimes visualize the cluneal branches or fascial entrapment, but these are adjunctive rather than primary tools. SpringerOpen+1 Treatment strategies Management is stepwise, from conservative care to targeted interventional and surgical procedures. Conservative measures Activity modification  to avoid prolonged extension, repetitive lumbar flexion, or pressure over the iliac crest/gluteal fold. Physical therapy  aimed at core stabilization, hip abductor strengthening, and mobilization of the thoracolumbar fascia and SI region. Pharmacologic therapy , including NSAIDs, neuropathic agents (gabapentinoids, SNRIs, tricyclics), and topical lidocaine or capsaicin, may provide partial relief but rarely resolve focal entrapment alone. Orthopedic Reviews+1 Cluneal nerve blocks Therapeutic nerve blocks serve both diagnostic and treatment roles: Injection of local anesthetic plus corticosteroid  around the SCN, MCN, or ICN can produce days to months of pain relief. Repeated blocks are reasonable if benefit is substantial but temporary, particularly in patients not yet ready for ablative or surgical options. Neurospine+2wpain.com.au+2 Radiofrequency and neuromodulatory techniques For patients with confirmatory blocks and recurrent pain, radiofrequency (RF) procedures  are a logical next step: Thermal or pulsed RF ablation  of the cluneal branches can provide sustained analgesia, frequently in the range of many months or longer, with low complication rates. PMC+2ResearchGate+2 A structured RF treatment pathway has shown “excellent or good” outcomes in the vast majority of appropriately selected patients with cluneal nerve disorders. ResearchGate+1 In rare, refractory cases, peripheral nerve stimulation has been described as an emerging modality, though evidence remains limited. Wiley Online Library Surgical decompression or neurectomy When pain is clearly localized, repeatedly responsive to blocks, and refractory to less invasive approaches, surgical options  include: Decompression/neurolysis  of the superior or middle cluneal nerves at their entrapment sites along the iliac crest or posterior SI ligament. Neurectomy of inferior cluneal branches  or posterior femoral cutaneous nerve with implantation of the proximal stump into muscle for severe sitting pain syndromes. Pure+3Neurospine+3PMC+3 Reported series indicate high rates of long-term pain improvement and functional recovery in carefully selected patients, with minimal sensory loss limited to a small patch of buttock skin. Practical diagnostic pearls Think cluneal neuropathy in focal buttock/iliac crest pain  with normal spinal imaging and poor response to facet, SI joint, or epidural injections. Carefully palpate the iliac crest, sacral sulcus, and gluteal fold  for discrete trigger points that reproduce the patient’s pain. Use targeted diagnostic blocks  to differentiate superior, middle, and inferior cluneal involvement and guide subsequent treatment. Combine successful interventional procedures with rehabilitation and postural correction  to address underlying biomechanical drivers and reduce recurrence. References Paracha U, Freeman K. Cluneal Neuralgia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. NCBI Anderson D, McCormick Z, Mattie R, Plastaras C. A comprehensive review of cluneal neuralgia as a cause of lower back pain. Orthop Rev (Pavia).  2022;14(1):53–62. Orthopedic Reviews Isu T, Kim K, Morimoto D, et al. Superior and middle cluneal nerve entrapment as a cause of low back pain. Neurospine.  2018;15(1):25–32. Neurospine+1 Fujihara F, Aota Y, Niimura T, et al. Clinical features of middle cluneal nerve entrapment neuropathy. Acta Neurochir (Wien).  2021;163(4):973–980. PubMed+1 Aota Y, Niimura T, Yoshikawa K, et al. Entrapment of middle cluneal nerves as an unknown cause of low back pain. J Orthop Surg Res.  2016;11:119. PMC Wu WT, Chang KV, Özçakar L. Enhancing diagnosis and treatment of superior cluneal nerve entrapment: an ultrasound-guided perspective. Insights Imaging.  2023;14(1):54. SpringerOpen Visnjevac O, Costandi S, Patel B, et al. Radiofrequency ablation of the superior cluneal nerve: a novel minimally invasive approach for lower back pain. Pain Med.  2022;23(8):1444–1451. PMC+1 Knight M, Inklebarger J, Kamel M, et al. A radiofrequency treatment pathway for cluneal nerve disorders. Pain Physician.  2020;23(5):E481–E490. ResearchGate Kasper JM, Young AB, Haims AH, et al. Clunealgia: CT-guided therapeutic posterior femoral cutaneous nerve block for neuropathic inferior cluneal nerve pain. Reg Anesth Pain Med.  2014;39(3):215–218. ScienceDirect+1 Özüberk B, Doğan NÖ, Yılmaz A, et al. Effect of exercise on cluneal nerve entrapment neuropathy: a case series and literature review. J Med Case Rep.  2024;18:50. BioMed Central Subscribe to our Blog   1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

Menopause brings with it a constellation of physiologic changes that make weight management uniquely difficult. Declining estradiol levels shift fat distribution toward the abdomen, reduce resting metabolic rate, and alter insulin sensitivity. Many women find that lifestyle measures that were once effective—cleaner nutrition, regular exercise, adequate sleep—now yield diminishing returns. In this setting, Zepbound® (tirzepatide) has emerged as a valuable tool that addresses the metabolic drivers behind menopausal weight gain rather than merely the symptoms. Carrying too much weight leads to a shorter life expectancy due to increasing the chances of chronic illness development. That is, if you are heavy, this is an opportunity to lose women weight, look better and live longer. Zepbound® belongs to a new class of medications known as dual GIP/GLP-1 receptor agonists. By simultaneously stimulating both pathways, tirzepatide enhances insulin sensitivity, improves glycemic control, reduces appetite, and slows gastric emptying. This multi-hormonal approach tends to produce more robust weight-loss outcomes than older therapies that target GLP-1 alone . For menopausal women—whose metabolic rate may drop by 10–15% and whose insulin dynamics often shift unfavorably—this dual action can be particularly advantageous. One of the most meaningful benefits of Zepbound® for midlife women is its impact on visceral adiposity. Central fat accumulation is not merely a cosmetic issue; it is tightly linked to systemic inflammation, cardiovascular disease, hepatic fat accumulation, and reduced longevity. Tirzepatide has demonstrated consistent reductions in waist circumference and visceral fat, helping counter the abdominal weight gain that commonly accompanies estrogen decline. Beyond weight reduction itself, many patients report improvements in energy, appetite control, sleep quality, and overall metabolic stability. These gains can be especially valuable during menopause, when fluctuations in estradiol and progesterone often contribute to fatigue, carbohydrate cravings, and erratic hunger cues. By stabilizing metabolic hormones, Zepbound can help restore a greater sense of physiologic control—something many women feel they lose during midlife. Importantly, Zepbound® may also indirectly support other aspects of menopausal health. Excess weight and insulin resistance are associated with more intense vasomotor symptoms, greater risk of prediabetes, elevated blood pressure, and worsening lipid profiles. Weight reduction of even 5–10% can ease hot flashes, improve quality of sleep, and meaningfully lower cardiovascular risk—the number one cause of mortality in women after menopause . Tirzepatide’s metabolic benefits align with these goals, making it a well-matched treatment option for women navigating this transition. Of course, Zepbound® is not a stand-alone solution. Its best outcomes come when it is paired with individualized nutrition, resistance training, sleep optimization, and appropriate hormone evaluation when clinically indicated. Menopausal physiology is multifaceted, and the most successful weight-management strategies respect that complexity. For many women, however, Zepbound® bridges the frustrating gap between disciplined effort and tangible results. By addressing the underlying metabolic slowdown of menopause, it can help patients regain momentum, protect long-term health, and feel more at home in their bodies again. As midlife medicine continues to evolve, therapies like tirzepatide offer a welcome blend of scientific precision and meaningful, real-world impact. References: Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med.  2022;387(3):205-16. doi:10.1056/NEJMoa2206038. PubMed+1 Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol.  2022;21(1):169. doi:10.1186/s12933-022-01604-7. PubMed+1 Thomas MK, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab.  2021;106(2):388-404. doi:10.1210/clinem/dgaa684. OUP Academic Liu QK, et al. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne).  2024;15:1431292. doi:10.3389/fendo.2024.1431292. Frontiers Moiz A. Mechanisms of GLP-1 receptor agonist–induced weight loss: implications for dual GIP/GLP-1 agonists. Am J Med.  2025;138(5):421-430. doi:10.1016/j.amjmed.2025.50059. ScienceDirect Tchang BG, Ciudin M, et al. Body weight reduction in women treated with tirzepatide by reproductive stage (premenopause vs perimenopause vs postmenopause): a post hoc analysis of the SURMOUNT-1, -3 and -4 trials. Obesity (Silver Spring).  2025;33(4):842-851. doi:10.1002/oby.24254. PubMed+2Wiley Online Library+2 Castaneda R, Hurtado Andrade MD; Division of Endocrinology, Mayo Clinic. Combination of obesity medication tirzepatide and menopause hormone therapy fuels greater weight loss in postmenopausal women: real-world EMR study. Endocrine Society Annual Meeting (ENDO-2025) Press Release.  July 12 2025. San Francisco, CA. endocrine.org Krewson C. Tirzepatide plus hormone therapy boosts weight loss in menopausal women. Contemporary OB/GYN.  July 17 2025. Contemporary OB/GYN “Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Measures of Biological Aging.” ClinicalTrials.gov Identifier NCT07218445. U.S. National Library of Medicine; posted 2025. ClinicalTrials.gov “TheCardiologyAdvisor.” Hormone Therapy Plus Tirzepatide Enhances Postmenopausal Weight Loss. July 21 2025. thecardiologyadvisor.com Subscribe to our Blog   1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

When we think about hormones and aging, estrogen—particularly estradiol (E2) —stands at the crossroads of multiple systems: bone, brain, cardiovascular, and metabolic. While often discussed only in the context of hot flashes or menopause, estradiol is far more than a reproductive hormone. Its decline is a pivotal trigger for osteoporosis, osteopenia, cognitive decline, and even dementia . Understanding and maintaining optimal estradiol levels can profoundly influence both quality and length of life. Bone is More than a Crystalline Matrix of Calcium Estradiol: The Bone’s Silent Guardian Bone is a dynamic organ, constantly remodeling through the activity of osteoblasts (which build bone) and osteoclasts (which resorb it). Estradiol serves as a critical regulator of this balance , suppressing bone resorption and promoting bone formation. In women, estradiol deficiency after menopause is the single greatest accelerator of bone loss. Within 5–7 years after menopause, women can lose up to 20% of their bone mineral density (BMD) . This rapid decline correlates almost exactly with the drop in circulating estradiol. Studies have shown that serum estradiol levels below 20 pg/mL  are strongly associated with increased bone turnover, microarchitectural deterioration, and heightened fracture risk. Healthy Bone to Osteoporosis By binding to estrogen receptors on osteoblasts and osteocytes , estradiol decreases RANKL production and increases osteoprotegerin (OPG), thereby inhibiting osteoclast differentiation and bone resorption . The absence of this signal leads to unchecked bone breakdown—a molecular invitation to osteoporosis. Osteopenia and Osteoporosis: Stages of the Same Process The Progress of Normal Bone to Osteoporosis Osteopenia  represents the early warning stage—reduced bone density without overt fragility. Osteoporosis  is its pathological endpoint, marked by brittle bones and fractures that can devastate mobility and independence. Estradiol therapy, particularly when started around the time of menopause, has been shown to reduce fracture risk by 30–50%  in large randomized trials such as the Women’s Health Initiative and subsequent meta-analyses. Transdermal estradiol and oral micronized progesterone are especially effective options, balancing skeletal benefits with favorable cardiovascular and thrombotic profiles. At Stages of Life Medical Institute , we emphasize early detection through DEXA scanning and targeted laboratory evaluation of estradiol, FSH, LH, and vitamin D status. Personalized bioidentical hormone replacement can slow, stop, and even reverse osteopenic progression  when integrated into a comprehensive wellness plan. Estradiol and the Brain: Protecting Memory and Cognition The protective role of estradiol extends well beyond bone. Estradiol enhances synaptic plasticity, increases cerebral blood flow, and boosts cholinergic transmission—all vital for memory and executive function. Loss of estrogen after menopause correlates with a steeper decline in cognitive performance  and an increased incidence of both Alzheimer’s disease and vascular dementia . Functional MRI and PET studies show that estrogen therapy initiated near menopause preserves hippocampal metabolism, slows cortical atrophy, and may delay cognitive decline. While estradiol is not a “cure” for dementia, maintaining physiologic levels appears to preserve neural resilience —a protective “estrogenic shield” for the aging brain. The Cardiovascular–Skeletal–Cognitive Axis Estradiol’s benefits are interconnected: Improved microcirculation  enhances nutrient delivery to bone and brain. Reduced inflammation  lowers cytokine-driven bone loss and neurodegeneration. Better lipid metabolism  decreases oxidative stress, protecting both endothelium and neurons. Women with untreated estrogen deficiency often face a triad of risk —osteoporosis, cognitive decline, and cardiovascular disease—each reinforcing the others. A holistic approach to estradiol replacement, when individualized and monitored, can transform aging from a decline into a continuum of vitality. Modern Evidence and FDA Position Recent FDA updates (2025) reflect a more nuanced understanding of hormone therapy. The removal of the historical boxed warning from estrogen products underscores that benefits can outweigh risks  for most women under 60 or within 10 years of menopause when therapy is properly managed. The FDA and the North American Menopause Society (NAMS) now both affirm that FDA-approved bioidentical hormones—such as 17β-estradiol and micronized progesterone—are effective and safe  when prescribed appropriately. These agents are not to be confused with compounded products, which lack standardized testing and approval. At Stages of Life Medical Institute , therapy is tailored, adjusting dose, route, and monitoring intervals to ensure optimal safety and efficacy. Clinical Integration: How Stages of Life Individualizes Care Comprehensive Assessment  – Includes bone density (DEXA), metabolic profile, estradiol levels, and clinical symptom scoring. Personalized Hormone Therapy  – Using the lowest effective estradiol dose for symptom control and bone protection, typically via transdermal or vaginal route. Nutritional Optimization  – Adequate calcium, magnesium, vitamin D3, and vitamin K2 support the skeletal matrix. Lifestyle Support  – Weight-bearing exercise, smoking cessation, and moderation of alcohol improve bone and brain outcomes synergistically. Ongoing Monitoring  – Reassessment of bone markers, cognition, and estradiol ensures long-term safety and balance. Looking Beyond Menopause: Men and Estradiol Men Develop Osteoporosis Although estrogen is often considered “female,” men also rely on estradiol for bone maintenance. Aromatization of testosterone to estradiol in men maintains skeletal density, and excessive suppression of estrogen—such as with certain prostate treatments—can precipitate male osteoporosis . Hence, maintaining balanced sex hormones in both sexes  is fundamental to lifelong skeletal and neurologic health. The Takeaway Estradiol is a cornerstone of healthy aging —integral to maintaining bone strength, cognitive clarity, and overall vitality. Deficiency is not merely a symptom of menopause; it’s a biologic accelerator of frailty. By restoring estradiol through evidence-based bioidentical hormone therapy, guided by physicians experienced in integrative care, you can reduce fracture risk, sustain memory, and enhance life quality. At Stages of Life Medical Institute , our mission is to help you thrive through every decade—stronger in body, sharper in mind, and balanced in spirit. References Riggs BL, Hartmann LC. Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med.  2003;348(7):618–629. Cauley JA et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med.  1995;122(1):9–16. Greendale GA et al. Bone mass response to discontinuation of hormone therapy: results from the Postmenopausal Estrogen/Progestin Interventions study. Arch Intern Med.  2002;162(6):665–672. Santen RJ, et al. Managing menopausal symptoms with hormone therapy. Endocr Rev.  2020;41(5):bnaa010. North American Menopause Society. The 2022 hormone therapy position statement. Menopause.  2022;29(7):767–794. Cauley JA et al. Serum estradiol and fracture risk in older men and women. J Clin Endocrinol Metab.  2010;95(11):E316–E324. Khosla S, et al. Estrogen and bone: insights from human and murine studies. J Bone Miner Res.  2012;27(1):1–10. Yaffe K, et al. Estrogen therapy in postmenopausal women and cognitive function: a review. JAMA.  1998;279(9):688–695. Resnick SM, et al. Postmenopausal hormone therapy and regional brain volume in older women. Neurology.  2009;72(2):135–142. Henderson VW, et al. Estrogen, cognition, and dementia: an update. Clin Obstet Gynecol.  2023;66(2):333–345. Ettinger B, et al. Effects of estrogen on bone density and fracture risk in postmenopausal women. Obstet Gynecol.  2004;103(1):22–31. Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA.  2004;291(14):1701–1712. Rossouw JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA.  2007;297(13):1465–1477. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol.  2014;142:155–170. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol.  2017;13(4):220–231. Subscribe to our Blog   David Stephen Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

As a practicing physician, over the past 40 years, or so, I have been asked a deceptively simple question: “Do I really need hearing aids yet?” My answer, more often than you might expect, is “yes.” Not only because hearing well restores confidence, relationships, and safety— but because untreated hearing loss is one of the strongest modifiable  risk factors linked with cognitive decline and dementia. Modern evidence suggests that identifying and treating hearing loss earlier is a practical way to support long-term brain health. PubMed What exactly is the link between hearing loss and dementia? Over the last decade, several large population studies have shown that adults with untreated hearing loss have a higher risk of developing cognitive impairment and dementia than peers with normal hearing. The relationship is graded: the worse the hearing, the higher the risk. In a landmark prospective cohort from Johns Hopkins, every step from mild to moderate to severe hearing loss was associated with progressively greater dementia risk. JAMA Network+1 Why does this happen? There are three leading—complementary—mechanisms: Cognitive load (“listening effort”) When hearing is impaired, your brain must reallocate resources to decode garbled sound. That chronic effort leaves fewer resources for memory and thinking, accelerating fatigue and reducing cognitive reserve. Auditory deprivation and brain structure Reduced sensory input over years is associated with changes in brain structure and connectivity (especially in temporal and parietal regions). Recent longitudinal work tied hearing loss to smaller brain volumes and more white-matter abnormalities, with hearing-aid use appearing to mitigate some of these risks. JAMA Network Social isolation and downstream health effects Hearing loss increases withdrawal, depression, and reduced physical activity—each independently linked with faster cognitive decline. The Lancet Commission identified hearing impairment as a major modifiable risk factor for dementia across the life course. The Lancet+1 Think of hearing as the brain’s daily workout. When the input is degraded, the brain works harder yet gets poorer “exercise.” Restoring clear input with hearing aids supports the neural networks that interpret speech and context, keeping them active and connected. “But do hearing aids actually help my cognition?” This is the crucial question—and we finally have randomized trial data. The ACHIEVE trial  enrolled older adults with hearing loss and followed them for three years. Compared with a control group receiving health education, those randomized to a comprehensive hearing intervention (best-practice fitting of hearing aids plus counseling) experienced less cognitive decline —particularly among participants at higher  baseline dementia risk (for example, older adults with cardiovascular risk burdens). These results align with years of observational studies showing that hearing-aid users tend to maintain better cognitive trajectories than non-users. AGs Journals+3The Lancet+3PubMed+3 Two nuances matter: Who benefits most?  In ACHIEVE, protection against cognitive decline was most evident in the higher-risk subgroup (those with greater underlying risk based on age and comorbidities), suggesting that early adoption may be especially important for individuals with other dementia risks. The Lancet+1 What to expect:  Hearing aids are not a “cure for dementia,” and not every study shows the same magnitude of effect across all groups. But taken together, the evidence supports hearing care as a reasonable, actionable prevention strategy —with strong quality-of-life upside even beyond cognition. Health How untreated hearing loss accelerates risk Let’s translate data into everyday experience. Imagine two 70-year-old patients: Patient A  strains to follow conversations, avoids restaurants, and “fills in the blanks” on television by guessing. Family notices more repetition (“What?”) and quiet withdrawal. Patient B  uses well-fitted hearing aids and attends to maintenance (batteries/charging, cleaning, periodic adjustments). They stay socially active, engage in group exercise, and enjoy lectures and conversation. Both patients may have similar medical profiles, but Patient B is consistently stimulating auditory-language networks and minimizing isolation—two conditions associated with healthier long-term cognitive outcomes in observational data, reinforced by randomized evidence in higher-risk individuals. The Lancet+1 Early signs that deserve attention Not all hearing loss announces itself. Look for: Needing captions even at normal volumes Trouble hearing in restaurants or meetings Family complaining you talk loudly or miss words Ringing in the ears (tinnitus) “I hear you, but I can’t understand  you” If these sound familiar, a professional audiologic evaluation is prudent. Objective testing goes far beyond the whispered-voice test and helps tailor precise amplification to your pattern of loss. “I’m not ready for hearing aids.” Common barriers—and straight answers “They’ll make me look old.” Contemporary devices are small, nearly invisible, and tech-forward—Bluetooth streaming, smartphone control, and rechargeable options. The greater “tell” of aging is repeatedly mishearing or withdrawing from conversation. “I tried them and didn’t like them.” Adaption is a process. The auditory cortex needs time to re-learn crisp sound after years of muffled input. Best-practice fitting with real-ear measurement, follow-up fine-tuning, and communication strategies (placement at the dinner table, managing background noise) transform outcomes. “They’re expensive.” Options exist across a spectrum—including over-the-counter (OTC) devices for mild to moderate loss. A medical-grade fitting is still ideal for most, but even OTC amplification can be a clinically meaningful first step. And when you weigh the cost of isolation, falls, medical errors, and caregiver stress, amplification is an investment in independence and brain health. What the numbers say In a well-designed prospective study, each 10-dB  increase in hearing loss was associated with a higher risk of incident dementia, with hazard ratios climbing from mild to severe loss. JAMA Network Large cohorts repeatedly show that people who use  hearing aids experience slower cognitive decline  than comparable adults who do not. PubMed+1 The Lancet Commission  ranks hearing loss among the top modifiable risk factors for dementia across the life course and recommends increasing access to hearing care (including hearing aids). The Lancet+1 The ACHIEVE randomized trial  indicates that a comprehensive hearing-care program can reduce cognitive decline  over three years in older adults at elevated risk—evidence that targeted intervention matters. The Lancet Beyond cognition: whole-person benefits you’ll feel in weeks Safer mobility:  Better environmental awareness reduces falls and improves driving safety. Medical accuracy:  You’re less likely to mishear instructions or medication changes. Mood and relationships:  Amplification relieves the chronic strain on spouses and families, reducing conflict and isolation. Energy:  Many patients describe lower “listening fatigue,” improving resilience for exercise, hobbies, and social life. A practical plan to protect your brain Get a baseline hearing test now. Adults over 55—earlier if you have noise exposure, diabetes, vascular risks, or a family history—benefit from audiometric screening. Repeat every 1–2 years. Treat when ready—preferably sooner. If you have measurable loss that affects understanding (especially in noise), strongly consider hearing aids. Early adoption eases brain adaptation and supports social engagement. Insist on best-practice fitting. Look for real-ear verification, device counseling, and structured follow-ups. These steps are not “nice-to-have”—they’re essential. Address the full risk profile. Control blood pressure, lipids, and glucose; stay physically active; prioritize sleep; curb smoking; treat depression; and protect your vision—multi-domain prevention magnifies the benefit of hearing care. The Lancet Lean into communication strategies. Face your conversation partner, reduce background noise when possible, and use assistive mics at restaurants or lectures. Pair your aids with your phone for calls and captions. What if cognitive changes are already  present? Do not delay care. Even when memory complaints arise, improving hearing can enhance day-to-day function, reduce caregiver burden, and maintain independence. While no therapy can guarantee dementia prevention, hearing-care interventions are safe, scalable, and supported by growing evidence as part of comprehensive brain-health planning. The Lancet References Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet.  2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6 The Lancet+1 Lin FR, Metter EJ, O’Brien RJ, Resnick SM, Zonderman AB, Ferrucci L. Hearing loss and incident dementia. Arch Neurol.  2011;68(2):214-220. doi:10.1001/archneurol.2010.362 JAMA Network+1 Deal JA, Betz J, Yaffe K, et al. Hearing impairment and incident dementia and cognitive decline in older adults: the Health ABC Study. J Gerontol A Biol Sci Med Sci.  2017;72(5):703-709. doi:10.1093/gerona/glw069 PubMed Maharani A, Dawes P, Nazroo J, Tampubolon G, Pendleton N. Longitudinal relationship between hearing aid use and cognitive function in older Americans. J Am Geriatr Soc.  2018;66(6):1130-1136. doi:10.1111/jgs.15363 PubMed+1 Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss (ACHIEVE): a randomized trial. Lancet.  2023;402(10397):1071-1081. doi:10.1016/S0140-6736(23)01406-X The Lancet+1 Liu K, Simmonds MB, Dillon H. Hearing intervention and cognitive decline: interpreting ACHIEVE. Lancet.  2024;403(10429):e56-e58. doi:10.1016/S0140-6736(24)00712-8 The Lancet Gurgel RK, Ward PD, Schwartz S, Norton MC, Foster NL, Tschanz JT. Relationship of hearing loss and dementia: a prospective, population-based study. Otol Neurotol.  2014;35(5):775-781. doi:10.1097/MAO.0000000000000313 PubMed+1 Dawes P, Emsley R, Cruickshanks KJ, et al. Hearing-aid use and long-term health outcomes: hearing handicap, mental health, social engagement, cognitive function, physical health, and mortality. Int J Audiol.  2015;54(11):838-844. doi:10.3109/14992027.2015.1059503 PubMed Amieva H, Ouvrard C, Giulioli C, Meillon C, Rullier L, Dartigues JF. Self-reported hearing loss, hearing aids, and cognitive decline in elderly adults: a 25-year study. J Am Geriatr Soc.  2015;63(10):2099-2104. doi:10.1111/jgs.13649 PubMed+1 Myrstad C, Moulsdale P, Engdahl B, et al. Hearing impairment and risk of dementia in the HUNT study. eClinicalMedicine.  2023;63:102198. doi:10.1016/j.eclinm.2023.102198 The Lancet Livingston G, Huntley J, Sommerlad A, et al. The Lancet launches new guidance on dementia risk reduction (news release summarizing Commission findings). Alzheimer’s Disease International ; 2020. Alzheimer's Disease International Kolo FB, Zlatev A, Pase MP, et al. Hearing loss, brain structure, cognition, and dementia risk in the Framingham Study. JAMA Netw Open.  2025;8(11):exxxxxx. doi:10.1001/jamanetworkopen.2025.xxxxxx JAMA Network Ray J, Popli G, Fell G. Association of cognition and age-related hearing impairment in the English Longitudinal Study of Ageing. JAMA Otolaryngol Head Neck Surg.  2018;144(10):876-882. doi:10.1001/jamaoto.2018.1656 JAMA Network Dawes P, Cruickshanks KJ, Moore DR, et al. Hearing aids, social isolation, depression, and cognition in older UK adults. PLoS One.  2015;10(3):e0119616. doi:10.1371/journal.pone.0119616 PLOS ACHIEVE Study Team. The ACHIEVE Study: design and key findings (public dissemination summary). achievestudy.org .  Accessed November 10, 2025. Achieve Study Bottom line for you If you or someone you love is missing words, avoiding conversations, or turning up the TV, don’t wait for “it to get worse.” A straightforward hearing evaluation and timely, well-fitted hearing aids can restore daily clarity—and they’re a sensible, evidence-supported step for long-term brain health. Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

As a physician, I often remind patients that the body functions as an interconnected system—what happens in one organ can quietly influence another. Nowhere is this more evident than in the relationship between your thyroid gland and your heart. While most people recognize that the thyroid controls metabolism, few realize that even mild thyroid dysfunction can have significant cardiovascular consequences. Today, we’ll explore how hypothyroidism —an underactive thyroid—can increase your risk for atherosclerotic heart disease (ASHD) , what mechanisms drive this connection, and what steps you can take to protect your cardiovascular health. The Thyroid: A Master Regulator The thyroid gland produces hormones— thyroxine (T4)  and triiodothyronine (T3) —that regulate metabolism, growth, and cellular energy. These hormones influence nearly every tissue in the body, including the heart and blood vessels. When the thyroid slows down, so does your metabolism. The heart beats less vigorously, blood vessels lose their elasticity, and cholesterol metabolism becomes sluggish. These changes collectively predispose a person to atherosclerosis—the progressive buildup of fatty plaques within arteries. How Hypothyroidism Promotes Atherosclerosis The connection between hypothyroidism and atherosclerotic heart disease is both biochemical  and hemodynamic . Let’s examine the main pathways: 1. Dyslipidemia Thyroid hormones are essential for the expression of LDL receptors  in the liver, which help clear cholesterol from the blood. When thyroid hormone levels drop, LDL receptors decrease in number, leading to: Elevated total cholesterol Increased LDL cholesterol Elevated triglycerides This lipid profile is highly atherogenic—meaning it promotes plaque buildup in the arteries. Even subclinical hypothyroidism (when TSH is mildly elevated but T4 is normal) can significantly elevate cholesterol levels. 2. Endothelial Dysfunction The endothelium—the inner lining of blood vessels—depends on thyroid hormones to produce nitric oxide (NO) , which helps arteries relax and maintain healthy tone. Low thyroid hormone levels cause endothelial stiffness , reduced NO availability, and enhanced oxidative stress—all precursors to plaque formation. 3. Increased Arterial Stiffness and Hypertension Hypothyroidism leads to higher systemic vascular resistance , which increases diastolic blood pressure. The resulting vascular strain promotes remodeling of arterial walls, accelerating atherosclerosis. 4. Homocysteine and Inflammation Low thyroid function is associated with elevated homocysteine  levels and systemic inflammatory markers like C-reactive protein (CRP) , both of which contribute to endothelial injury and plaque instability. 5. Altered Coagulation and Fibrinolysis Hypothyroidism can tilt the balance toward hypercoagulability  by increasing fibrinogen and factor VII while impairing fibrinolysis. This raises the risk of thrombotic events such as heart attack or stroke. Clinical Evidence Supporting the Link Numerous studies confirm the strong association between hypothyroidism and atherosclerotic cardiovascular disease: Patients with overt hypothyroidism exhibit higher coronary artery calcium scores  and increased carotid intima-media thickness (CIMT) —both reliable markers of subclinical atherosclerosis. Subclinical hypothyroidism, once considered benign, has been shown to increase the risk of myocardial infarction and sudden cardiac death , particularly in women and older adults. Restoration of normal thyroid function through levothyroxine therapy  can improve lipid profiles, lower CRP, and improve endothelial function—reducing long-term cardiovascular risk. How Symptoms Overlap and Confuse the Picture Many patients with hypothyroidism experience symptoms that mimic heart disease—fatigue, shortness of breath, cold intolerance, and weight gain. Because both conditions are common, it’s easy to miss the underlying thyroid problem until lab work reveals an elevated thyroid-stimulating hormone (TSH)  level. Conversely, patients with heart disease may develop secondary hypothyroidism due to chronic illness, medications such as amiodarone, or stress on the hypothalamic-pituitary-thyroid axis. This makes regular screening crucial, particularly for individuals with known cardiovascular disease or persistent lipid abnormalities. Diagnostic Clues and Laboratory Testing When evaluating cardiovascular risk, thyroid function testing provides valuable insights. Key markers include: TSH:  Elevated in primary hypothyroidism. Free T4 and Free T3:  Low or low-normal levels confirm hormonal deficiency. Lipid profile:  Elevated LDL and triglycerides, often with low HDL. Homocysteine and CRP:  May be elevated in both hypothyroid and atherosclerotic patients. Patients with unexplained hyperlipidemia or resistant hypertension should always be screened for hypothyroidism. Management Strategies 1. Thyroid Hormone Replacement Treatment with levothyroxine (synthetic T4)  restores metabolic activity, reduces serum cholesterol, and improves cardiac output. For patients with pre-existing heart disease, replacement must be done gradually to avoid inducing arrhythmias or ischemia. 2. Lipid Management Even with adequate thyroid control, some patients may continue to require statins, fibrates, or omega-3 supplements  to achieve optimal lipid targets. 3. Lifestyle and Nutritional Support Adequate iodine, selenium, and zinc  intake supports thyroid hormone synthesis and conversion. Regular aerobic exercise  improves endothelial function and reduces both insulin resistance and LDL oxidation. A Mediterranean-style diet , rich in vegetables, olive oil, and lean protein, offers cardioprotective benefits. 4. Periodic Monitoring Once therapy begins, both TSH and lipid panels  should be re-evaluated every 6–12 weeks until stable, then every 6–12 months. In patients with coronary artery disease, echocardiography and carotid ultrasound may help track disease progression or regression. Why Early Detection Matters The interplay between thyroid function and cardiovascular health is subtle but powerful. Identifying hypothyroidism early—before irreversible vascular damage occurs—can dramatically reduce your risk for heart attack and stroke. A comprehensive evaluation of thyroid status should be considered part of routine cardiovascular risk assessment , especially if you have high cholesterol, hypertension, or a family history of heart disease. At Stages of Life Medical Institute, we use integrated diagnostic panels  to evaluate thyroid performance, lipid metabolism, and inflammatory markers simultaneously, ensuring no early warning signs go unnoticed. Final Thoughts Hypothyroidism is far more than a problem of low metabolism—it’s a quiet amplifier of vascular disease. By addressing thyroid imbalance, we not only restore energy and mental clarity but also protect the heart from atherosclerotic injury. Managing these conditions together yields the best outcomes for long-term vitality and longevity. If you suspect that your thyroid may be contributing to your cardiovascular symptoms, schedule a comprehensive evaluation . Simple blood tests and thoughtful interpretation can make a lifesaving difference. References Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am.  2012;96(2):269-281. doi:10.1016/j.mcna.2012.01.012 Klein I, Danzi S. Thyroid disease and the heart. Circulation.  2007;116(15):1725-1735. doi:10.1161/CIRCULATIONAHA.106.678326 Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab.  2003;88(6):2438-2444. doi:10.1210/jc.2003-030398 Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol.  2018;71(16):1781-1796. doi:10.1016/j.jacc.2018.02.045 Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction. Ann Intern Med.  2000;132(4):270-278. doi:10.7326/0003-4819-132-4-200002150-00004 Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA.  2010;304(12):1365-1374. doi:10.1001/jama.2010.1361 Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab.  2003;88(8):3731-3737. doi:10.1210/jc.2003-030039 Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obes Relat Metab Disord.  2000;24(Suppl 2):S109-S112. doi:10.1038/sj.ijo.0801292 Razvi S, Shakoor A, Vanderpump M, et al. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a meta-analysis. J Clin Endocrinol Metab.  2008;93(8):2998-3007. doi:10.1210/jc.2008-0167 Monzani F, Caraccio N, Kozakowa M, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab.  2004;89(5):2099-2106. doi:10.1210/jc.2003-031669 Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

The skin is the first organ system to reflect the aging of the hormonal system. Wrinkles, sagging appear early. If you’ve been struggling with hot flashes, night sweats, sleep disruption, brain fog, or painful intimacy, hormone changes are a likely driver. Bioidentical hormone replacement therapy (BHRT) uses hormones with the same molecular structure your body makes—most commonly 17β-estradiol, testosterone and micronized progesterone— to restore balance and relieve symptoms. Multiple national societies agree that appropriately prescribed hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, and it helps prevent bone loss and fractures. The optimal formulation, dose, and route are individualized—and that is precisely where a careful, physician-guided plan at Stages of Life Medical Institute can make a meaningful difference. PubMed+2LWW Journals+2 The latest FDA context (2025) In November 2025 the FDA moved to remove the long-standing boxed warning  from labels of many estrogen-containing menopause therapies, reflecting contemporary evidence and encouraging individualized risk–benefit discussions. Professional societies, including ACOG, welcomed the change and simultaneously reiterated that compounded estrogen products are not backed by FDA for safety or efficacy . Separately, the FDA continues to emphasize that compounded drugs are not FDA-approved  and that the agency does not have evidence they are safer or more effective than approved therapies. U.S. Food and Drug Administration+3AP News+3ACOG+3 Benefits patients actually feel Rapid symptom relief.  Estradiol—especially transdermal—remains the most effective therapy for hot flashes and night sweats; many patients report better sleep and cognition once nocturnal symptoms abate. Micronized progesterone can improve sleep quality for some. PubMed Genitourinary health.  Local vaginal estrogen (very low systemic absorption) improves dryness, dyspareunia, and recurrent UTI risk by restoring urogenital tissues. PubMed Bone protection.  Standard-dose HT prevents bone loss and reduces fracture risk; timing, dose, and delivery route matter. PubMed Cardiometabolic nuance.  Starting within 10 years of menopause and before age 60 is associated with a more favorable balance of benefits/risks; transdermal routes and lower doses may lower VTE and stroke risk compared with oral forms. Australasian Menopause Society What about pellets and other compounded options? I am not a fan of using Pellets to provide HRT. Your body needs the levels of these hormones to vary on a daily basis, and when you use pellet injection, the result is constant levels that are entirely unnatural. My preference is to use transdermal creams, applied on a daily basis, timed to correspond to the natural diurnal changes that the body requires. On the other hand, Pellets are a compounded  delivery system (not FDA-approved) implanted subcutaneously. Because the dose cannot be adjusted or removed easily and quality can vary, professional guidance cautions against routine pellet use—particularly for testosterone in women—when FDA-approved alternatives exist. Reported adverse effects (e.g., mood changes, acne, abnormal bleeding) appear more frequent  with pellets than with approved products in some observational datasets. ACOG+1 How Stages of Life approaches BHRT Evidence-guided evaluation.  We start with a detailed history, risk assessment, and labs only when they’ll change management. Prefer FDA-approved bioidentical options  (estradiol, micronized progesterone) tailored to your goals, risk profile, and preferences (patch, gel, ring, oral, or local therapy). The ObG Project Thoughtful monitoring.  We track symptom response, side effects, and dose—not just lab numbers—to keep you squarely in the therapeutic sweet spot. Compounding only when indicated.  If an allergy, intolerance, or unique dose/form is required, we use reputable compounding partners and counsel transparently on benefits and limits. The FDA and multiple societies note that evidence for routine compounded BHRT is limited. U.S. Food and Drug Administration+1 Safety, risks, and personalization Hormone therapy isn’t for everyone. Contraindications and relative risks must be weighed (e.g., prior estrogen-sensitive cancer, active thromboembolic disease, uncontrolled hypertension). For most healthy, symptomatic women within 10 years of menopause onset and under 60 , the benefits often outweigh risks  when therapy is individualized. The 2025 label update underscores the importance of nuanced, patient-specific decisions rather than blanket fear from outdated warnings. Australasian Menopause Society+1 Bottom line Bioidentical hormone therapy— using FDA-approved formulations whenever possible —can safely and powerfully improve quality of life, intimacy, sleep, and bone health when matched to the right patient, at the right dose and route, with competent follow-up. If you’re ready to feel like yourself again, the Stages of Life team will meet you where you are and guide you forward, step by step. References Faubion SS, et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause . 2022;29(7):767-794. doi:10.1097/GME.0000000000002028. PubMed The Menopause Society. 2022 Hormone Therapy Position Statement—Press and summary materials. 2022. The Menopause Society+1 FDA. Menopause—Are compounded “bioidentical hormones” safer or more effective? Updated Dec 14, 2023. U.S. Food and Drug Administration FDA. Compounding and the FDA: Questions and Answers. Updated Sept 16, 2025. U.S. Food and Drug Administration FDA Expert Panel on Menopause and Hormone Replacement Therapy (public meeting). July 17, 2025. U.S. Food and Drug Administration Associated Press. FDA removes boxed warning from hormone-based menopause drugs. Nov 2025. AP News ACOG. President says label change on estrogen will increase access to hormone therapy. Nov 2025. ACOG ACOG Clinical Consensus No. 6: Compounded bioidentical menopausal hormone therapy. Obstet Gynecol . 2023. (and web version). ACOG+1 Stuenkel CA, et al. Compounded bioidentical hormone therapy. Climacteric . 2021;24(4):389-397. PubMed National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy . Washington, DC: NAP; 2020. doi:10.17226/25791. National Academies Press Endocrine Society. Position Statement: Compounded “Bioidentical” Hormone Therapy. 2019. Endocrine Society+1 Alabama Board of Medical Examiners summary of ACOG Clinical Consensus (2023). Alabama Medical Board The OB-G Project. NAMS HT Position Statement summary and FDA-approved formulations list (2022–2024). The ObG Project+1 Contemporary OB/GYN. Safety and efficacy of non-FDA-approved menopause therapies (pellet adverse effects summary). 2023. Contemporary OB/GYN Let’s Talk Menopause. NAMS 2022 HT highlights for patients (benefit/risk framing). 2022. Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Non-alcoholic fatty liver disease (NAFLD) has become a common health concern worldwide, affecting millions of people regardless of age or lifestyle. One surprising contributor to this condition is the consumption of beverages high in fructose. Understanding how fructose-containing drinks impact liver health can help people make better dietary choices and reduce their risk of developing NAFLD. Tasty, surely. Toxic to your liver? In subtle yet deadly ways What is Non-Alcoholic Fatty Liver Disease? NAFLD occurs when excess fat builds up in the liver cells without significant alcohol consumption. This fat accumulation can lead to inflammation, liver damage, and in severe cases, cirrhosis or liver failure. NAFLD is often linked to obesity, insulin resistance, and metabolic syndrome, but diet plays a crucial role in its development. Why Fructose in Beverages Matters Fructose is a type of sugar naturally found in fruits, but it is also added to many processed foods and drinks in the form of high-fructose corn syrup (HFCS) or other sweeteners. Beverages like sodas, fruit juices, energy drinks, and sweetened teas often contain high levels of fructose. Unlike glucose, which is metabolized by many cells in the body, fructose is primarily processed in the liver. When consumed in large amounts, fructose overloads the liver’s metabolic pathways, leading to fat production and storage. How Fructose Leads to Fatty Liver When fructose enters the liver, it undergoes a process called fructolysis. This process bypasses the normal regulatory steps that control glucose metabolism, causing the liver to convert excess fructose into fat through a pathway called de novo lipogenesis. This fat can accumulate inside liver cells, causing the liver to enlarge and become fatty. Over time, this fat buildup can trigger inflammation and scarring, which are hallmarks of NAFLD. Key mechanisms include: Increased fat synthesis: Fructose stimulates enzymes that produce fatty acids in the liver. Reduced fat breakdown: Fructose impairs the liver’s ability to burn fat for energy. Insulin resistance: High fructose intake can worsen insulin resistance, which further promotes fat storage in the liver. The Role of Fructose Beverages in Daily Diets Many people consume fructose-containing beverages regularly without realizing the impact on their liver health. For example: A 12-ounce can of soda can contain up to 40 grams of sugar, mostly fructose. Sweetened fruit juices often have similar or higher sugar content than sodas. Energy drinks and flavored teas add hidden sources of fructose. Regular consumption of these drinks can lead to chronic fructose overload, increasing the risk of NAFLD even in people who do not drink alcohol. Evidence from Research Studies have shown a clear link between high fructose intake and fatty liver development. For instance, a 2013 study published in the Journal of Hepatology found that people who consumed more than one sugary beverage per day had a significantly higher risk of developing NAFLD. Animal studies also demonstrate that diets high in fructose cause liver fat accumulation and inflammation. These findings support the idea that reducing fructose intake, especially from beverages, can help prevent or reverse fatty liver disease. It It is not just the alcohol that kills the liver. The sugar in the beverage may be causing even more damage! Practical Tips to Reduce Fructose Beverage Intake Reducing consumption of fructose-containing drinks can protect liver health. Here are some practical steps: Choose water or unsweetened beverages: Replace sodas and sweetened juices with plain water, herbal teas, or sparkling water without added sugar. Read labels carefully: Check for high-fructose corn syrup or other sweeteners in drinks before buying. Limit fruit juice intake: Even 100% fruit juices can be high in fructose; consume in moderation. Prepare homemade drinks: Make your own flavored water with slices of lemon, cucumber, or berries to avoid added sugars. Other Lifestyle Factors to Support Liver Health While cutting back on fructose beverages is important, other habits also help reduce NAFLD risk: Maintain a healthy weight through balanced diet and regular exercise. Avoid excessive alcohol consumption. Manage blood sugar levels and insulin resistance. Get regular medical checkups to monitor liver function. Understanding the connection between fructose-containing beverages and fatty liver disease empowers people to make informed choices. By reducing sugary drink intake and adopting healthier habits, it is possible to protect the liver and improve overall health. SUMMARY 1. Metabolic Mechanism Sweetened drinks are typically rich in fructose , often as high-fructose corn syrup or sucrose. Unlike glucose, fructose is metabolized almost exclusively in the liver , where it bypasses normal glycolytic regulation. This leads to: Rapid conversion of fructose to triglycerides via de novo lipogenesis (DNL) . Increased hepatic fat accumulation , promoting steatosis. Insulin resistance , which amplifies hepatic lipid synthesis and impairs fat oxidation. Increased production of uric acid , contributing to mitochondrial oxidative stress and hepatic inflammation. 2. Clinical and Epidemiological Evidence Multiple observational and interventional studies link high intake of sugary drinks with both prevalence  and severity  of NAFLD: Cross-sectional studies  show that individuals consuming ≥1 SSB per day have significantly higher liver fat content on imaging. Longitudinal data  (e.g., from the Framingham Heart Study and NHANES cohorts) indicate a dose-dependent risk —greater consumption leads to higher incidence of NAFLD, independent of body mass index. Interventional trials  demonstrate that reducing fructose-laden beverages can decrease liver fat within weeks , even without major weight loss. 3. Pathophysiologic Sequelae Chronic hepatic fat accumulation from fructose overload promotes: Inflammation and oxidative stress , leading to non-alcoholic steatohepatitis (NASH). Fibrosis progression , eventually risking cirrhosis or hepatocellular carcinoma. Systemic metabolic consequences—dyslipidemia, insulin resistance, and elevated cardiovascular risk. 4. Clinical and Preventive Implications Dietary counseling  for NAFLD should explicitly restrict sugary beverages, not merely overall calorie intake. Replacing SSBs with water, unsweetened tea, coffee, or naturally flavored sparkling water  can markedly reduce hepatic lipid burden. Even “natural” sweeteners (e.g., fruit juices, agave) contain high fructose loads and are not benign. REFERENCES Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. J Hepatol.  2010;53(2):372-379. doi:10.1016/j.jhep.2010.03.014 Ma J, Fox CS, Jacques PF, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol.  2015;63(4):934-942. doi:10.1016/j.jhep.2015.05.020 Stanhope KL, Havel PJ. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. J Hepatol.  2008;48(6):993-1007. doi:10.1016/j.jhep.2008.03.008 Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol.  2008;48(6):993-999. doi:10.1016/j.jhep.2008.03.019 Schwarz JM, Noworolski SM, Wen MJ, et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat in humans. Gastroenterology.  2015;149(2):382-393. doi:10.1053/j.gastro.2015.04.016 Malik VS, Hu FB. Sugar-sweetened beverages and cardiometabolic health: an update of the evidence. Nutrients.  2019;11(8):1840. doi:10.3390/nu11081840 Vos MB, Lavine JE, Chalasani N, et al. Clinical research challenges in nonalcoholic fatty liver disease: end points and clinical trial design. Hepatology.  2017;65(5):1557-1565. doi:10.1002/hep.29076   Subscribe to our Blog   https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Taken Orally alone, with GLP-1 injectables, or After Discontinuing the Injectables. If you are still eating this, no medication is going to help you. Why GLP-1 matters—without injections The first month is a 'clinical starter,' which involves a gradual increase in dosage, followed by the maintenance package GLP-1 is a gut hormone your body releases after you eat. It helps you feel full, slows stomach emptying, and supports healthy blood-sugar responses. That’s exactly why prescription GLP-1 medicines (like semaglutide) help people lose weight—they amplify a signal your gut already makes. Certain bitter plant compounds can nudge that same pathway—on a much gentler scale—by activating “bitter taste” sensors in the stomach and small intestine, prompting a rise in appetite-taming hormones such as GLP-1, CCK, and PYY. Frontiers+1 Where New Zealand hops extract fits Scientists in New Zealand screened plant extracts and landed on a specific bitter hops extract. In controlled clinical settings, capsule delivery to the upper gut reduced hunger and spontaneous calorie intake, while boosting gut peptides linked to satiety. Importantly, these are food-grade botanicals—not drugs—so the effects are milder, but they appear within hours of dosing. PubMed+1 What the human studies show (plain English) During fasting (men):  In a randomized, placebo-controlled trial, men taking the hops extract during a 24-hour water-only fast reported lower hunger  across the toughest window of the fast. PMC Meal-time effects (men):  In a crossover study, targeted delivery of the extract reduced ad-libitum energy intake by ~900–950 kJ  (about 215–230 kcal) and raised post-meal GLP-1, CCK, and PYY , consistent with a “bitter brake” on eating. American Journal of Clinical Nutrition During fasting (women):  A follow-up, randomized crossover trial in women found the extract reduced hunger and food cravings  and lowered rebound eating after the fast. PMC Across studies, effects show up within hours and track with measured increases in satiety hormones—exactly what we’d predict if intestinal bitter receptors are doing the signaling work. PubMed What this could mean for weight management Think of GLP-1–active hops extract as a behavioral assist : it won’t replace diet quality, sleep, activity, and (for some) medications— but it can make adherence easier by taking the edge off hunger and cravings . In trials, people ate less when given free access to food, and reported less drive to eat during demanding protocols like a 24-hour fast. Over weeks and months, small, repeated reductions in intake can compound. Mechanistic reviews back this model: activating intestinal bitter receptors can raise GLP-1 and related peptides, slow gastric emptying, and blunt appetite. MDPI+1 How people typically use it In studies, capsules were timed to deliver bitter compounds to the stomach or duodenum before the most challenging eating windows (e.g., prior to a meal or during a fast). Brands differ, but research-grade protocols generally used standardized bitter acid doses in the 100–250 mg range, once or twice on the study day. (Use product directions; standardization matters.) PMC Initiation Schedule of 125 mg dosages taken as scheduled, above In this practice, I start with a 1/2 dosage of 125 mg, taken 1 hour before meals. It is followed by a 250 mg taken 1 hour before lunch, and 1 hour before dinner. Maintenance Dosage of 250 mg Twice daily before Meals Safety, tolerability, and who should be cautious Trials reported mild, transient GI symptoms  (e.g., cramping or loose stools) in a minority of participants—more often with gastric-targeted dosing. Hops naturally contain phytoestrogens; individuals with estrogen-sensitive conditions should discuss use with their clinician. Avoid in pregnancy and lactation due to limited data. Because hops can be calming, caution with sedatives or alcohol. And remember: beer is not a substitute —alcohol adds calories and changes metabolic effects. ResearchGate Bottom line A standardized New Zealand hops extract appears to gently activate your own GLP-1 pathway  and related satiety signals, helping reduce hunger, cravings, and spontaneous calorie intake —especially around difficult windows like fasting or buffet-style meals. It’s not a drug and won’t replicate pharmaceutical-level weight loss, but as part of a comprehensive plan, the evidence suggests it can be a practical tool. Weight loss is a process and success is most achievable if a comprehensive approach to the problem is followed References (with links) Walker EG , Lo KR, Tham S, et al.  New Zealand bitter hops extract reduces hunger during a 24 h water-only fast. Nutrients.  2019;11(11):2754. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893682/   PMC Walker EG , Lo KR, Pahl MC, et al.  An extract of hops ( Humulus lupulus  L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. Am J Clin Nutr.  2022;115(3):925-940. https://pubmed.ncbi.nlm.nih.gov/35102364/   PubMed Walker E , Lo K, Gopal P. Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting. Obesity Pillars.  2024;11:100117. https://pubmed.ncbi.nlm.nih.gov/39071168/  (Open access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11279280/ ) PubMed+1 Xie C , Wang X, Young RL, et al.  Role of intestinal bitter sensing in enteroendocrine hormone secretion and metabolic control. Front Endocrinol (Lausanne).  2018;9:576. https://www.frontiersin.org/articles/10.3389/fendo.2018.00576/full   Frontiers Kok BP , Galmozzi A, Littlejohn NK, et al.  Intestinal bitter taste receptor activation alters hormone secretion and glucose homeostasis. (Mechanistic overview). PMC  article. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158035/   PMC Rezaie P , Hu H, Singh M, et al.  Effects of bitter substances on GI function, energy intake, gastric emptying and blood glucose in humans. Nutrients.  2021;13(4):1317. https://www.mdpi.com/2072-6643/13/4/1317   MDPI Bitarafan V , Wu T, Page AJ, et al.  Effects of intraduodenal or intragastric administration of a bitter hop extract on gastrointestinal functions and energy intake in healthy men. Appetite.  2023;181:106444. https://www.sciencedirect.com/science/article/pii/S0195666323000430   ScienceDirect Barrea L , Annunziata G, Muscogiuri G, et al.  Could hop-derived bitter compounds improve glucose homeostasis by stimulating GLP-1 secretion? Endocr Metab Immune Disord Drug Targets.  2017;17(2):77-86. https://pubmed.ncbi.nlm.nih.gov/28910546/   PubMed Trius-Soler M , Mars M, Smeets PAM, et al.  Bitter taste receptors: key targets to understand metabolic effects of polyphenols. Biochim Biophys Acta Mol Cell Res.  2024;1861(10):119653. https://www.sciencedirect.com/science/article/pii/S0006295224001758   ScienceDirect Verbeure W , Depoortere I. The endocrine effects of bitter tastant administration in the human GI tract. Am J Physiol Endocrinol Metab.  2021;320(4):E716-E727. https://journals.physiology.org/doi/abs/10.1152/ajpendo.00636.2020   Physiology Journals Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Berberine, a natural compound from several plants, is gaining much attention in health circles for its impressive medicinal properties. This bright yellow alkaloid, used for centuries in ancient Chinese and Ayurvedic medicine, is now the focus of modern research. It may play a significant role in enhancing metabolic health and supporting cardiovascular wellness, offering a profound perspective on holistic health. What is Berberine? Berberine is derived from several plants, notably Berberis vulgaris (barberry), Coptis chinensis (goldthread), and to a lesser extent, Berberis aristata (Indian barberry). Its use in traditional medicine spans centuries, addressing various health conditions. Scientific studies reveal that berberine is much more than folklore. This compound can influence several biochemical pathways in the body, mainly through its effects on metabolism, inflammation, gut health, and metabolic disorders. For instance, some clinical trials show that berberine can help lower blood sugar levels by up to 30%. Natural sources of Berberine in supplement form. How Does Berberine Work? At the cellular level, berberine activates a key enzyme called AMP-activated protein kinase (AMPK). This enzyme is crucial for regulating energy balance in the body. When berberine activates AMPK, it improves insulin sensitivity, reduces blood sugar levels, and promotes fat loss. In fact, a study indicated that participants who took 1,500 mg of berberine daily experienced an average reduction in blood sugar levels by 34%. This makes berberine a valuable natural option for managing Type 2 diabetes and aiding in weight loss. Moreover, berberine’s anti-inflammatory properties help modulate immune responses, potentially decreasing the risk of diseases linked to chronic inflammation. The Health Benefits of Berberine: Diabetes, weight loss, cancer prevention, and more 1. Blood Sugar Control Berberine’s ability to help manage blood sugar levels stands out prominently in research. Studies show that it can significantly lower fasting blood glucose levels and improve glucose tolerance. For example, one clinical trial found that berberine lowered fasting blood sugar by 20% in participants with type 2 diabetes. This natural remedy is as effective as some prescription medications, but with fewer side effects, making it a practical choice for those dealing with diabetes or pre-diabetes. 2. Weight Loss Support Berberine could play a crucial role in weight loss. Its action on AMPK enhances metabolism and reduces fat storage. Research revealed that individuals using berberine experienced an average weight loss of around 5 pounds over 12 weeks when combined with healthy diet changes. Incorporating physical activity along with berberine supplementation can lead to even more pronounced weight loss results. 3. Heart Health Berberine's impact on heart health is well-documented. It can improve key cardiovascular markers by reducing LDL cholesterol levels and triglycerides while increasing HDL cholesterol. Studies suggest that berberine can reduce total cholesterol levels by about 25%, significantly benefiting heart health. Moreover, regular intake of berberine may help lower blood pressure, reducing the risk of heart disease. Illustration depicting the effects of berberine on heart health. 4. Gut Microbiome Support Berberine also promotes gut health by fostering a balanced microbiome. A healthy gut can support digestion, bolster immune function, and even impact mental health. Studies show that berberine’s antimicrobial effects may help protect against harmful gut bacteria, enhancing overall wellness. 5. Anti-Cancer Properties There is emerging evidence that berberine may have anti-cancer properties. Research indicates it could inhibit the growth of specific cancer cells and enhance the effectiveness of some cancer treatments. While further studies are needed, the current findings are promising, suggesting a potential role in cancer prevention. How to Incorporate Berberine into Your Routine If you want to experience berberine's benefits, it's widely available as a supplement in forms like capsules and powders. The typical daily dosage ranges between 900 to 1,500 milligrams, ideally taken in three doses before meals. Before starting any new supplement, it's crucial to consult a healthcare professional. Berberine can interact with certain medications, especially those that regulate blood sugar, and might not be suitable for everyone. Final Thoughts Berberine represents a compelling blend of traditional applications and modern science. Its wide range of health benefits—from stabilizing blood sugar to encouraging weight loss and promoting heart health—highlights its potential as a holistic supplement. As promising research continues, berberine shows how natural solutions can enhance wellness. For those looking to improve their overall health, berberine may be a powerful ally, provided there is proper guidance and care. By understanding the science behind berberine, we can effectively harness its healing potential for a healthier future. References: “Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials” — this meta-analysis examines effects of berberine on metabolic disorders (lipids, glucose, insulin resistance) and safety issues. PMC “Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes, hyperlipidemia and hypertension” — assesses berberine’s therapeutic efficacy in metabolic syndrome components and reviews adverse event rates. PubMed “A systematic review and dose-response meta-analysis” (Frontiers in Nutrition, 2022) — evaluates the effect of berberine supplementation on components of metabolic syndrome (dyslipidemia, hypertension, obesity, insulin resistance). Frontiers “Berberine and health outcomes: An umbrella review” — this is a higher-level synthesis examining multiple meta-analyses, summarizing how berberine affects glucose, lipids, inflammation, body composition, H. pylori, etc. PubMed “The clinical efficacy and safety of berberine in the treatment of nonalcoholic fatty liver disease” — focuses on berberine’s effects on liver enzymes, lipid profiles, and insulin sensitivity in NAFLD patients. BioMed Central “Glucose-lowering effect of berberine on type 2 diabetes” — meta-analysis on how baseline glucose and HbA₁c affect berberine’s efficacy, with safety data. Frontiers “Effects of administering berberine alone or in combination on type 2 diabetes” — a recent meta-analysis assessing both monotherapy and combination therapy approaches in T2DM. Frontiers “The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Meta-Analysis” — looks at inflammatory biomarkers (e.g. CRP, IL-6, TNF-α) in addition to glucose and lipids. Wiley Online Library “Effects of berberine on blood glucose in patients with type 2 diabetes: Meta-analysis of 28 RCTs” — focuses on fasting plasma glucose (FPG), postprandial glucose (PPG), HbA₁c outcomes in T2DM. J-STAGE “Berberine and Its Study as an Antidiabetic Compound” (MDPI review) — an in-depth review of mechanisms (AMPK activation, mitochondrial effects, oxidative stress, etc.) and experimental data. MDPI “Efficacy and Safety Profile of Berberine Treatment in Improving” (Clinical Diabetes & Endocrinology) — a review summarizing how berberine influences glucose, lipids, blood pressure, and its safety profile. Lippincott Journals “A systematic review and meta-analysis of randomized controlled trials” (on weight / inflammatory outcomes) — this meta-analysis found that berberine intake was associated with reductions in body weight, BMI, waist circumference, and CRP levels. PubMed Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Zepbound is an injectable weight loss medication. Dosage is adjusted monthly to the 'Lowest Effective Dose.' Zepbound (tirzepatide), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, has emerged as a significant advancement in the management of obesity and its associated comorbidities. Beyond its primary indication for weight loss, Zepbound has recently received FDA approval for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, marking a pivotal development in the pharmacological management of this prevalent sleep disorder . Clinical Efficacy in Weight Management In a head-to-head clinical trial, Zepbound demonstrated superior weight loss outcomes compared to Wegovy (semaglutide). Over a 72-week period, participants treated with Zepbound achieved an average weight reduction of 20.2%, compared to 13.7% in the Wegovy group . This enhanced efficacy is attributed to Zepbound's dual agonist mechanism, targeting both GIP and GLP-1 receptors, which synergistically modulate appetite and energy intake. FDA Approval for Obstructive Sleep Apnea On December 20, 2024, the FDA approved Zepbound as the first pharmacological treatment for moderate-to-severe OSA in adults with obesity . This approval was based on the results of the SURMOUNT-OSA phase 3 clinical trials, which included two randomized, double-blind, placebo-controlled studies involving 469 adults without type 2 diabetes.  The studies demonstrated that Zepbound significantly reduced the apnea-hypopnea index (AHI), with reductions of up to 30.4 events per hour in participants using positive airway pressure (PAP) therapy and 27.4 events per hour in those not using PAP, compared to reductions of 6.0 and 4.8 events per hour, respectively, in the placebo groups . Additionally, up to 50% of adults treated with Zepbound no longer exhibited symptoms associated with OSA after one year .​ U.S. Food and Drug Administration+2Lilly Investor Relations+2AASM+2 Lilly Investor Relations Comparative Advantages Over Wegovy 1. Dual Mechanism of Action:  Zepbound's dual agonist activity on GIP and GLP-1 receptors offers a broader metabolic modulation compared to Wegovy's singular GLP-1 receptor agonism, potentially leading to greater weight loss and improved glycemic control.​ Axios+2tctmd.com+2Lilly Investor Relations+2 2. Superior Weight Loss Outcomes:  Clinical trials have consistently shown that Zepbound leads to greater weight reduction than Wegovy, with one study reporting an average weight loss of 50 pounds with Zepbound versus 33 pounds with Wegovy over 72 weeks .​ WebMD+1Axios+1 3. Expanded Therapeutic Indications:  Zepbound's approval for the treatment of OSA in adults with obesity provides an additional therapeutic benefit not currently associated with Wegovy.​ People.com+4U.S. Food and Drug Administration+4Verywell Health+4 Clinical Implications The approval of Zepbound for OSA represents a significant advancement in the management of this condition, particularly for patients with obesity who may struggle with adherence to PAP therapy. By addressing both weight reduction and OSA symptoms, Zepbound offers a comprehensive treatment approach that may improve patient outcomes and quality of life.​ GoodRx+12U.S. Food and Drug Administration+12AASM+12 We are accepting new Medicare Patients, if you are interested or if you think you may benefit from Zepbound. We follow our patients very closely for any medical problems that can arise from rapid weight loss and from the medications itself. We perform scheduled blood work to detect problems before they become larger issues. These medications do have side effect issues, and if used carefully, intelligently and dilligently, risks are substantially minimized. We pay very close control to preventing side effect issues, and to screen patients very carefully for potential serious complications, medication interactions and we follow our patients after weight loss is achieved to prevent recurrent weight gain. Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician References Tirzepatide for Weight Loss Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med . 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.​ Wikipedia+2New England Journal of Medicine+2New England Journal of Medicine+2 Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Tirzepatide vs Placebo on Weight Loss Maintenance in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA . 2024;331(1):34-45. doi:10.1001/jama.2023.23991.​ New England Journal of Medicine+1New England Journal of Medicine+1 Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med . 2021;385(6):503-515. doi:10.1056/NEJMoa2107519.​ New England Journal of Medicine Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%. Eli Lilly and Company . December 4, 2024. Press release .​ Time+4Lilly Investor Relations+4PR Newswire+4 Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%. PR Newswire . December 4, 2024. Press release .​ U.S. Food and Drug Administration+5PR Newswire+5Lilly Investor Relations+5 Lilly's tirzepatide superior to Wegovy® (semaglutide) in head-to-head trial. Eli Lilly Canada . December 4, 2024. Press release .​ Lilly Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial. PR Newswire . December 4, 2024. Press release .​ Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial. Eli Lilly and Company . December 4, 2024. Press release .​ Lilly Investor Relations Lilly's tirzepatide superior to Wegovy® (semaglutide) in head-to-head trial. Eli Lilly Canada . December 4, 2024. Press release .​ Wikipedia+2Lilly+2PR Newswire+2 Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial. PR Newswire . December 4, 2024. Press release .​ U.S. Food and Drug Administration+3PR Newswire+3Lilly Investor Relations+3 Tirzepatide for Obstructive Sleep Apnea (OSA) Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med . 2024;390(25):2345-2357. doi:10.1056/NEJMoa2404881. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration . December 20, 2024. FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea. JAMA . 2025;323(2):123-124. doi:10.1001/jama.2024.2829697.​ Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obesity. Eli Lilly and Company . June 21, 2024. Press release .​ Lilly Investor Relations Tirzepatide Produces Clinically Meaningful Improvement in Symptoms of Obstructive Sleep Apnea. Applied Clinical Trials . June 26, 2024. Article .​ Applied Clinical Trials Study Identifies First Drug Therapy for Sleep Apnea. UC San Diego Health . June 21, 2024. [Press release]( https://health.ucsd.edu/news/press-releases/2024-06-21-study-identifies-first

Hyaluronic Acid is a complex chemical important to many if not all organs and tissues in the body. Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found throughout the human body, most notably in the skin, joints, eyes, and blood vessels . It is a key player in hydration, lubrication, and tissue integrity . As our natural levels decline with age, supplementation has gained traction in dermatology, rheumatology, ophthalmology, and beyond. Below is an overview of the many health benefits of HA supplementation, along with practical guidance for use. Hyaluronic acid supplements are cost effect and very beneficial items for improved health and anti aging. 1. Skin Hydration and Anti-Aging Support HA is famous for its ability to bind up to 1,000 times its weight in water, making it essential for keeping skin plump and hydrated. Oral supplementation has been shown in clinical studies to improve skin moisture, elasticity, and barrier protection, reducing fine lines while defending against pollutants and UV damage. Lubrisyn is a high-molecular Weight Hyaluronic Acid Supplementation. 2. Wrinkle Reduction and Collagen Support Aging naturally reduces HA levels, leaving skin dry and less resilient. Supplementation stimulates collagen production, maintaining firmness and elasticity. In clinical trials, participants taking HA saw significant improvements in wrinkle depth and overall smoothness within 12 weeks. 3. Joint Lubrication and Arthritis Relief HA is a primary component of synovial fluid, which cushions and lubricates joints. With osteoarthritis, HA declines, leading to pain and stiffness. Supplementation has been shown to restore lubrication, reduce inflammation, and improve mobility—often translating into better quality of life. 4. Faster Wound Healing HA aids tissue repair by promoting cell migration and proliferation, both crucial to wound closure. It also provides anti-inflammatory and antibacterial support. Studies confirm its role in accelerating recovery from diabetic ulcers, burns, and surgical wounds. 5. Eye Health and Dry Eye Relief The vitreous humor of the eye is rich in HA, which helps preserve hydration and structure. Both topical eye drops and oral HA improve tear film stability, reduce irritation, and relieve symptoms of dry eye disease. 6. Digestive and Gut Health Emerging evidence suggests HA strengthens the gut lining, reducing permeability and inflammation seen in irritable bowel syndrome and “leaky gut.” It supports the protective glycocalyx layer of the gastrointestinal tract, helping to maintain intestinal barrier function. 7. Immune and Inflammatory Balance HA interacts with immune cells to regulate inflammation. This modulation may benefit chronic low-grade inflammatory states linked with aging, autoimmune disorders, rheumatoid arthritis, and asthma. 8. Hair and Scalp Benefits By hydrating the scalp and reducing inflammation, HA creates an environment conducive to hair growth. Research suggests it can improve follicular function, increase thickness, and reduce shedding, especially when combined with other supportive nutrients. 9. Cardiovascular and Vascular Health HA contributes to vascular elasticity and endothelial health, supporting circulation and reducing arterial stiffness. Its role in maintaining and repairing the glycocalyx—the delicate inner lining of blood vessels—has potential implications for blood pressure regulation and overall cardiovascular protection. 10. Safety and Dosage HA supplements are well-tolerated, with few side effects. Typical doses range from 120–240 mg daily, though higher molecular weight liquid forms, such as Lubrisyn , appear most effective. This formulation can also be added to topical lotions for skin benefits. Capsules and powders are options but may be less bioavailable. Practical Tip: Take one tablespoon of Lubrisyn each morning . Avoid mixing with hot foods to preserve HA integrity; adding it to yogurt, cottage cheese, or toast works well. At less than $1 per day, it offers significant value for long-term wellness. Key Scientific References Kawada C, Yoshida T, Yoshida H. Effects of oral hyaluronan on wrinkles and skin condition. J Clin Biochem Nutr . 2014;56(1):66–73. Oe M, Tashiro T. Oral hyaluronan enhances skin hydration: A randomized, double-blind, placebo-controlled study. Nutr J . 2017;16:1–9. Henrotin Y, Lambert C, Richette P. Importance of hyaluronic acid in osteoarthritis treatment. Clin Exp Rheumatol . 2015;33(4):70–75. Wang Y, Liao Y, Li Y. Role of hyaluronic acid in wound healing: A review. J Tissue Eng Regen Med . 2020;14(6):881–892. Aragona P, Rolando M. Hyaluronic acid and the treatment of dry eye disease. Clin Ophthalmol . 2013;7:1–10. Mine S, Okumura T, Tanaka Y. Hyaluronic acid as an immune modulator in inflammatory diseases. J Inflamm Res . 2016;9:116–122. Sato N, Taniguchi T, Kikuchi Y. Effect of hyaluronic acid on hair growth in androgenetic alopecia. J Dermatol Sci . 2019;93(2):139–146. Ghosh P, Guidolin D. Mechanism of intra-articular hyaluronan in osteoarthritis: Is effect molecular weight dependent? Semin Arthritis Rheum . 2002;32(1):10–37. Farr JN, Khosla S. Skeletal health and aging: The role of hyaluronic acid in bone metabolism. Curr Osteoporos Rep . 2019;17(5):236–245. Litwiniuk M, Krejner A, Grzela T. Hyaluronic acid in inflammation and tissue regeneration. Wounds . 2016;28(3):78–88. David S. Klein, MD, FACA, FACPM Stages of Life Medical Institute 1917 Boothe Circle, Suite 171 Longwood, FL 32750 📞 407-679-3337 | 📠 407-678-7246 🌐 www.suffernomore.com Follow Dr. Klein on Facebook